@insidepharma

Biopharma Operator & Strategic Advisor | Founder, Katogen | Board Member | PubCo CEO | M&A, Capital Strategy | Read My Newsletter: https://xitter.cf/t.co/CISSuxuCBe

 United States
katogen.com/
Joined May 2011
  • Tweets3.7K
  • Following580
  • Followers2.6K
333Media

Katogen Insights: A 1957 Vertigo Drug and a $2 Billion Deal

Doug Drysdale, Founder, Katogen

Article · @insidepharma
220

Katogen Insights: What the Moderna Squeeze Did to the Rest of Biotech

Doug Drysdale, Founder, Katogen

Article · @insidepharma
2
7
784

Katogen Insights: What Lilly Bought Foghorn for $380 Million

Doug Drysdale, Founder, Katogen

Article · @insidepharma
228

Katogen Insights: The Clause That Decides Whether a Milestone Is Real

Doug Drysdale, Founder, Katogen

Article · @insidepharma
1
262

Katogen Insights: Interpreting an Unusually Large Anxiety Effect Size

Doug Drysdale, Founder, Katogen

Article · @insidepharma
1
1
267

Katogen Insights: How Long Should a Nine-Year-Old Stay on Semaglutide?

Doug Drysdale, Founder, Katogen

Article · @insidepharma
164

Katogen Insights: The Arithmetic Behind a $795 Million Epilepsy Deal

Doug Drysdale, Founder, Katogen

Article · @insidepharma
1
231

Katogen Insights: What You Own When the Model Designs the Molecule

Doug Drysdale, Founder, Katogen

Article · @insidepharma
231

Katogen Insights: Lilly Is Suing Sellers of a Drug It Has Not Launched

Doug Drysdale, Founder, Katogen

Article · @insidepharma
191

Katogen Insights: What Novo Nordisk Can't Buy With Its Balance Sheet

Doug Drysdale, Founder, Katogen

Article · @insidepharma
245

Katogen Insights: Buying a Mechanism Before Its Market Exists

Doug Drysdale, Founder, Katogen

Article · @insidepharma
292

Katogen Insights: What History Says About Otsuka's New ADHD Drug

Doug Drysdale, Founder, Katogen

Article · @insidepharma
3
611
Load more